PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 20260 citations

Evaluation of the Safety of Taking Brexpiprazole During the Lactation Period.

View Full Paper
AFAkari FukudaGOGen OyanagiSKSaya Kikuchi

Key Points

  • The aim is to evaluate the safety of brexpiprazole during the lactation period and its effects on infants.
  • Evaluated brexpiprazole monotherapy at doses of 1-2 mg/day
  • Monitored newborns and infants for withdrawal symptoms and adverse events
  • Assessed outcomes within the first month postpartum
  • No withdrawal symptoms observed in newborns or infants
  • No serious adverse events reported during the study
  • Initial evidence supports safety of brexpiprazole use during lactation

Abstract

This study suggests that BPZ monotherapy (1-2 mg/day) during lactation does not lead to withdrawal symptoms or serious adverse events in newborns or infants within the first month postpartum. This initial evidence may help inform breastfeeding decisions among mothers receiving BPZ monotherapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Fukuda et al. (2026) studied this question.

synapsesocial.com/papers/698827b40fc35cd7a8846a26https://doi.org/10.1177/15568253251408037
Ask AI
Helpful
Bookmark
Share
View Full Paper